Tags

Type your tag names separated by a space and hit enter

Nonalcoholic fatty liver disease.
Rev Gastroenterol Disord. 2002; 2(1):11-9.RG

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses a broad clinicopathologic spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which may advance to cirrhosis and end-stage liver disease. Steatosis alone does not appear to be progressive. The prevalence of NAFLD averages 20% and that of NASH, 2% to 3%, making these conditions the most common liver diseases in the United States. NAFLD is associated with insulin resistance, which may be evident clinically with obesity, type 2 diabetes mellitus, and hypertriglyceridemia. The pathogenesis of NAFLD consists of hepatic fat accumulation and oxidative stress with formation of free radicals. The clinical diagnosis is based on the presence of the insulin resistance syndrome and exclusion of alcohol abuse as well as viral, autoimmune, genetic, and drug-induced liver diseases. Liver biopsy is essential for diagnosis but may not be necessary for clinical management. Treatment is aimed at correcting the risk factors for NAFLD and using potentially hepatoprotective agents. Ursodeoxycholic acid and betaine appear particularly promising in early trials.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Liver Transplant Program, Stanford University Medical Center, Stanford, CA, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12122975

Citation

Yu, Andy S., and Emmet B. Keeffe. "Nonalcoholic Fatty Liver Disease." Reviews in Gastroenterological Disorders, vol. 2, no. 1, 2002, pp. 11-9.
Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord. 2002;2(1):11-9.
Yu, A. S., & Keeffe, E. B. (2002). Nonalcoholic fatty liver disease. Reviews in Gastroenterological Disorders, 2(1), 11-9.
Yu AS, Keeffe EB. Nonalcoholic Fatty Liver Disease. Rev Gastroenterol Disord. 2002;2(1):11-9. PubMed PMID: 12122975.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nonalcoholic fatty liver disease. AU - Yu,Andy S, AU - Keeffe,Emmet B, PY - 2002/7/19/pubmed PY - 2002/8/14/medline PY - 2002/7/19/entrez SP - 11 EP - 9 JF - Reviews in gastroenterological disorders JO - Rev Gastroenterol Disord VL - 2 IS - 1 N2 - Nonalcoholic fatty liver disease (NAFLD) encompasses a broad clinicopathologic spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which may advance to cirrhosis and end-stage liver disease. Steatosis alone does not appear to be progressive. The prevalence of NAFLD averages 20% and that of NASH, 2% to 3%, making these conditions the most common liver diseases in the United States. NAFLD is associated with insulin resistance, which may be evident clinically with obesity, type 2 diabetes mellitus, and hypertriglyceridemia. The pathogenesis of NAFLD consists of hepatic fat accumulation and oxidative stress with formation of free radicals. The clinical diagnosis is based on the presence of the insulin resistance syndrome and exclusion of alcohol abuse as well as viral, autoimmune, genetic, and drug-induced liver diseases. Liver biopsy is essential for diagnosis but may not be necessary for clinical management. Treatment is aimed at correcting the risk factors for NAFLD and using potentially hepatoprotective agents. Ursodeoxycholic acid and betaine appear particularly promising in early trials. SN - 1533-001X UR - https://www.unboundmedicine.com/medline/citation/12122975/Nonalcoholic_fatty_liver_disease_ L2 - http://www.diseaseinfosearch.org/result/4280 DB - PRIME DP - Unbound Medicine ER -